Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
RDIF and Stelis Biopharma partner to supply 200 million doses of the Sputnik V vaccine19-03-2021
19-03-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Stelis concludes US$ 195m Series B and Series C fund raise Significant interest from marquee long term investors19-03-2021
Strides Pharma Science Ltd - 532531 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Strides Pharma Science Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here17-03-2021
Strides Pharma Science Ltd - 532531 - Voting Results Of Postal Ballot Pursuant To Regulation 44 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 And Scrutinizer'S Report
With reference to above, we would like to inform you that the aforesaid ordinary resolution has been passed by the Members of the Company with requisite majority. The resolution is deemed as passed on the last date of the e-voting i.e., March 15, 2021. Please find enclosed the Voting Results along with Scrutinizer's Report. This is for your information and records.17-03-2021
India emerges global manufacturing hub for Covid-19 vaccine Sputnik V
Gland Pharma to make 252 mn doses, Hetero 100 mn doses, Strides may also join the fray17-03-2021
Strides gets USFDA nod for potassium chloride for oral solution
Strides Pharma Science Limited (Strides) has announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited, Singapore, has15-03-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Potassium Chloride for Oral Solution15-03-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Sub: Allotment of shares under Strides ESOP 2016 Plan The Board of Directors of the Company in their meeting held today have allotted 15,150 equity shares of face value of Rs. 10/- each to the eligible employees who have exercised their stock options under Strides ESOP 2016 Plan. These shares shall rank in pari passu with the existing equity shares of the Company in all respects. Consequent to above, the paid-up share capital of the Company has increased from Rs. 89,64,58,140/- consisting of 8,96,45,814 equity share of Rs. 10/- each to Rs. 89,66,09,640/- consisting of 8,96,60,964 equity shares of Rs. 10/- each. Request you to take the same on record.12-03-2021
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 V R Sasindran Nair05-03-2021
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Shrikrishna D Kamat/ Sneha S Kamat03-03-2021